Home  »  Company  »  Bal Pharma Ltd  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Bal Pharma Ltd.

Mar 31, 2018

1. Company Overview

Bal Pharma Limited (the company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act, 1956. Its shares are listed on two recognized stock exchanges in India. The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

1.1 Basis of Preparation of Financial Statements

a) Compliance with Ind AS

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.

For all periods up to and including the year ended 31 March 2017, the Company prepared its financial statements in accordance accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP).

These financial statements for the year ended 31 March 2018 are the first the Company has prepared in accordance with Ind AS. Refer to note 51 for information on how the Company adopted Ind AS.

b'' Historical Cost Convention

The financial statements have been prepared on a historical cost basis, except for the following assets and liabilities which have been measured at fair value or revalued amount:

- Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments),

- Defined Benefits and other long term employment benefits

c) Functional and Presentational Currency

The financial statements are presented in INR which is the functional currency for the Company. All amounts disclosed in the financial statements and notes have been rounded to the nearest lakhs.

d) Use of Estimates and Judgments

The preparation of financial statements in conformity with Ind AS requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent liabilities on the date of financial statements and reported amounts of revenue and expenses for that year. Actual result could differ from these estimates. Any revision to accounting estimates is recognized prospectively.

The estimates and underlying assumptions are reviewed by management at each reporting date. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of revision or future periods if the revision affects both current and future periods.

Critical accounting estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below:

Judgments

1) Recognition of Deferred Income Taxes

2) Recognition Research and Developments Costs (Note no 37)

Estimates

1) Useful lives of various of Property, Plant and Equipment (Note 3 & 4)

2) Fair Value of Financial Instruments (Note No 48)

3) Accounting for Defined Benefit Plan (Note No 43)

4) Expected Credit Losses

e) Current vs Non-Current Classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle

- Held primarily for the purpose of trading

- Expected to be realised within twelve months after the reporting period, or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle

- It is held primarily for the purpose of trading

- It is due to be settled within twelve months after the reporting period, or

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities. The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The group has identified twelve months as its operating cycle.

c) Rights, preferences and restrictions attached to equity shares:

The Company has only one class of equity shares having par value of '' 10 each. Each holder of the equity share, as reflected in the records of the Company as of the date of the shareholders'' meeting, is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders'' meeting.

The Company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

d) There have been no buy back of shares, issue of shares by way of bonus share or issue of share pursuant to contract without payment being received in cash for the period of five years immediately preceding the balance sheet date.

A) Details of securities, repayment and interest of term loans (including current maturities of long-term debt):

(a) Loan from Exim Bank outstanding as at 31 March 2018: Rs. 2.40 Cr (31 March 2017 : Rs. 3.60 Cr : 01 April 2016: Rs. 4.80 Cr)

Security

i. The Loan is secured by first charge on the entire moveable property, Plant and equipment of the Company by way of hypothecation and pari passu first charge by way of equitable mortagage on all immovable property, Plant and equipment of Unit 1, 2, 3 and 4 of the Company.

Repayment and interest

ii. The loan was repayable in 20 equal quarterly installments of Rs. 0.30 crore each, starting from April 2015.

iii. Interest was payable on EXIM bank LTLMR plus 250 basis points which is currently at 12.70% per annum.

(b) Loan from Corporation Bank outstanding as at 31 March 2018: Rs. 9.52 Cr (31 March 2017: Rs. 10.84 Cr : 01 April 2016: Rs. 6.85 Cr)

Security

i. The loan is secured by entire moveable property, plant and equipment of the Company, both present and future, belonging to unit I, unit 2, unit 4 of the Company.

Repayment and interest

ii. The loan was repayable in 80 monthly installments starting from April 2017.

iii. Interest was payable on LTLMR plus 5.60% which is currently at 13.75% per annum

(c) Loan from Yes Bank outstanding as at 31 March 2018: Rs. 3.56 cr (31 March 2017 : Rs. 0.75 Cr : 01 April 2016: Rs. Nil)

Security

i. The loan is secured by mortagage of the property of unit 5, sangli and personal guarantee of managing director.

Repayment and interest

ii. The loan was repayable in 48 monthly installments starting from June 2017.

iii. Interest was payable on at 10.75% per annum

(d) Loan from Tata Capital outstanding as at 31 March 2018: Rs. 14.00 Cr (31 March 2017 : Rs. Nil : 01 April 2016: Rs. Nil)

Security

i. The loan is secured by mortagage of the property of unit 6, Udaipur and personal guarantee of managing director.

Repayment and interest

ii. The loan was repayable in 48 monthly installments starting from June 2017.

iii. Interest was payable on at 10.75% per annum

(e) Loan from The South India Bank Limited outstanding as at 31 March 2018: '' 4.86 Cr (31 March 2017 : Rs. 5.16 Crores :01 April 2016: Rs. Nil) "

Security

i. The loan is secured by mortagage of the Land at Vasanth Nagar

Repayment and interest

ii. The loan was repayable in 154 monthly installments starting from March 2018.

iii. Interest was payable on at 10.65% per annum

(f) Loan from The South India Bank Limited outstanding as at 31 March 2018: Rs. 3.39 Cr (31 March 2017: Rs. Nil : 01 April 2016: Rs. Nil) "

Security

i. The loan is secured by mortagage of the Land at Vasanth Nagar

Repayment and interest

ii. The loan was repayable in 180 monthly installments starting from April 2018.

iii. Interest was payable on at 10.65% per annum

(g) Loan from Kotak Mahindra Bank Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.17 Cr (31 March 2017: Rs. 0.63 " Cr : 01 April 2016: Rs. 1.01 Cr) "

Repayment and interest

i. The loan was repayable in 36 monthly installments starting from July 2015.

ii. Interest was payable on at 11.75% per annum

(h) Loan from Kotak Mahindra Bank Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.59 Crores (31 March 2017: Rs. Nil 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 36 monthly installments starting from Aug 2017.

ii. Interest was payable on at 16.50 % per annum

B) Details of securities, repayment and interest of Other loans (including current maturities of long-term debt):

(a) Loan from Magma Fincorp Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.53 Cr (31 March 2017: Rs. Nil : 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 24 monthly installments starting from Aug 2017.

ii. Interest was payable on at 16.00% per annum

(b) Loan from Tata Capital Financial Services Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.53 Cr (31 March 2017: Rs. Nil : 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 24 monthly installments starting from July 2017.

ii. Interest was payable on at 15.94% per annum

(c) Loan from Capital First Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.62 Cr (31 March 2017: Rs. Nil : 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 24 monthly installments starting from Aug 2017.

ii. Interest was payable on at 15.00% per annum

(d) Loan from Equitas Small Finance Bank Limited (Unsecured)outstanding as at 31 March 2018: Rs. 0.44 Cr (31 March 2017: Rs. Nil : 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 36 monthly instalments starting from November 2017.

ii. Interest was payable on at 16.50% per annum

(e) Loan from Neo Growth Private Limited (Unsecured) outstanding as at 31 March 2018: Rs. 0.44 Cr (31 March 2017 : Rs. Nil : 01 April 2016: Rs. Nil)

Repayment and interest

i. The loan was repayable in 36 monthly instalments starting from May 2018.

ii. Interest was payable on at 18.00% per annum

C) The Vehicle Loans have been taken on the hypothecation of vehicles

D) There are no defaults in repayment of principal or interest to lenders as at the balance sheet date.

All secured loans payable on demand and secured short term loans from banks are secured by first charge by way of hypothecation of all the stocks, book debts and other current assets (both present and future) and carries interest rate @ 9.75% to 13.65%

Note: The Company is also involved in other lawsuits, claims, investigations and proceedings, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

2 Disclosure with respect to Micro, Small and Medium Enterprises

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum in accordance with the ‘Micro, Small and Medium Enterprises Development Act, 2006'' (‘the MSMED Act''). Accordingly, based on the information available with the Company, no amount is payable in respect of such entities as at 31 March 2018. (31 March 2017: Nil, 1 April, 2016: Nil)

3 Confirmations

Balances of Trade Receivables, Trade Payables, Loans and Advances, Receivables and Payables are subject to confirmation / reconciliation, if any

4 Subsequent Events

Declaration of Dividend - The Board of Directors of the Company has proposed a 10% dividend on face value of the shares, subject to the approval by Shareholders at AGM

5 Note on Suspended Activities in Unit located in Pune

The Management of the Company has decided to suspend the operations of its IV fluids and parenterals manufacturing facility at Pune as this unit has been consistently incurring operational losses due to various reasons such as higher costs of raw materials, escalation in production cost, employee cost, lack of adequate orders and thin margins on products manufactured. The above have led to a situation wherein any further efforts to restore the profitability of the unit will be furtile. This decision was taken as part of the restructuring exercise undertaken by the Company to streamline its operations and to exit from its noncore businesses, so that further deterioration of its noncore business revenues can be plugged.

6 Employee benefits

In accordance with applicable Indian laws, the Company provides for gratuity, a defined benefit retirement plan (Gratuity Plan). The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee''s last drawn salary and the number of years of employment with the Company.

The following tables summarise the components of net benefit expense recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for gratuity benefit.

7 Segment reporting

The Company is primarily engaged in a single business segment of manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

In accordance with Ind AS-108 “Operating Segments”, information about geographical areas has been given in the Consolidated Financial Statements of Bal Pharma Ltd., and therefore, no separate disclosure on geographical areas is given in these financial statements.

8 Export Benefits

The Company has accounted an amount of Rs. 339.51 Lakhs (31 March 2017 : Rs. 402.30 Lakhs ) being the net amount of credit under various export incentive schemes as announced under Foreign trade Policy. The management has represented that the same will be either received in cash or utilized for off-setting customs duty on future imports. The accumulated amount outstanding on this account as on 31 March 2018 is Rs. 494.31 Lakhs (31 March 2017: Rs. 603.81 Lakhs) and the same is reflected under Balance with Government Authorities

9 Leasing Arrangements

The company''s significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rental payable are charged as rent under note No. 34

10. Financial risk management

The Company has exposure to following risks arising from financial instruments- Market Risk

- Credit Risk

- Liquidity Risk

The Company''s board of directors has overall responsibility for the establishment and oversight of the Company''s risk management framework. The Company''s risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company''s activities.

The Company''s audit committee oversees how management monitors compliance with the Company''s risk management policies and procedures and reviews the adequacy of the risk management framework in relations to the risks faced by the Company.

A Market Risk

1) Currency Risk

The Company operates internationally and a major portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk to the extent that there is mismatch between the currencies in which its sales and services and purchases from overseas suppliers in various foreign currencies. Market Risk is the risk that changes in market prices such as foreign exchange rates will effect company''s income or value of its holding financial assets/ instruments. The exchange rate between the Rupee and foreign currencies has changed substantially in recent years and may fluctuate substantially in the future. Consequently, the results of the Company''s operations are adversely affected as the Rupee appreciates/ depreciates against US dollar (USD), Euro (EUR), Dhirams (AED) and Others.

2) Cash Flows and Interest rate Risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates, in cases where the borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

(a) Exposure to Interest Rate Risk

The interest rate profile of the Company''s interest-bearing financial instruments as reported

(b) Fair value sensitivity analysis for fixed-rate instruments

The Company''s fixed rate instruments are carried at amortised cost. They are therefore not subject to interest rate risk as defined Ind AS 107, since neither the carrying amount nor future cash flows will fluctuate because of change in market interest rates.

(c) Cash flow sensitivity analysis for variable-rate instruments

A reasonable possible change of 2% (200 basis points) in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

B Liquidity Risk

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.

The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

Maturities of financial liabilities:

The tables below analyse the Company''s financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

C Credit Risk

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. The Company''s exposure to credit risk is limited to the carrying amount of financial assets recognised at the date of the balance sheet, as summarised in the table below. The Company periodically assesses the financial reliability of the counter party taking into account the financial condition, current economic trends, analysis of historical bad debts and ageing of accounts receivable. Individual customer limits are set accordingly.

Credit risk on cash and cash equivalents is limited as generally invest in deposits with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies. Advances to Related Parties are for business purposes and The Company assesses the credit risk on the these advances on a regular basis and does not for see any event of default.

Trade receivables and unbilled revenue are typically unsecured and are derived from revenue earned from customers. Credit risk has always been managed by each business segment through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain. The Company is exposed to credit risk in the event of non-payment by customers. Credit risk concentration with respect to trade receivables is mitigated by the Company''s large customer base. Adequate expected credit losses are recognized as per the assessments and as such has provided for a expected credit loss of Rs. 15.50 Lakhs ( 31 March 2017 : Nil, 1 April 2016: Nil )

11 Capital Management

For the purpose of the Company''s capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders of the Company. The primary objective of the Company''s capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions, annual operating plans and long term and other strategic investment plans. In order to maintain or adjust its capital structure, the Company may adjust the amount of dividends paid, return the capital to shareholders, issue new shares or adjust its short term borrowings. The current capital structure of the Company is equity based backed with short term borrowings.

12. First-time adoption of Ind AS

The Company''s financial statements for the year ended March 31, 2018 are the first financial statements prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. The adoption of Ind AS was carried out in accordance with Ind AS 101, using April 1, 2016 as the transition date. Ind AS 101 requires that all Ind AS standards and interpretations that are effective for the first Ind AS financial statements for the year ended March 31, 2018, be applied consistently and retrospectively for all fiscal years presented.

All applicable Ind AS have been applied consistently and retrospectively wherever required. The resulting difference between the carrying amounts of the assets and liabilities in the financial statements under both Ind AS and Indian GAAP as at the transition date have been recognized directly in equity at the transition date.

Exemptions and exceptions availed

Set out below are the applicable Ind AS 101 optional exemptions and mandatory exceptions applied in the transition from previous GAAP to Ind AS.

1. Ind AS optional exemptions

a. Deemed Cost

As per Ind AS 101, a Company may elect to:

(i) measure an item of property, plant and equipment at the date of transition at its fair value and use that fair value as its deemed cost at that date.

(ii) use a previous GAAP revaluation of an property, plant and equipment at or before the date of transition as deemed cost at the date of the revaluation, provided the revaluation was, at the date of the revaluation, broadly comparable to:

a. Fair Value

b. or cost or depreciated cost under Ind AS adjusted to reflect, for example, changes in a general or specific price index.

(iii) se carrying value of property, plant and equipment, intangible assets and investment properties as on the date of transition to Ind AS (which are measured in accordance with previous GAAP and after making adjustments relating to decommissioning liabilities prescribed under Ind AS 101) if there has been no change in its functional currency on the date of transition.

As permitted by Ind AS 101, the Company has elected to continue with the carrying values under previous GAAP for all the items property, plant and equipment. The same election has been made in respect of intangible assets also.

2. Ind AS mandatory exemptions

a. Estimates

An entity''s estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Ind AS estimates as at 1 April 2016 are consistent with the estimates as at the same date made in conformity with previous GAAP The Company made estimates for Impairment of financial assets based on expected credit loss model in accordance with Ind AS at the date of transition as these were not required under previous GAAP

b. Classification and measurement of financial assets

Ind AS 101 requires an entity to assess classification and measurement of financial assets on the basis of the facts and circumstances that exist at the date of transition to Ind AS.

Accordingly, the Company has determined the classification of financial assets based on facts and circumstances that exist on the date of transition.

c. Derecognition of financial assets and liabilities

As per Ind AS 101, an entity should apply the derecognition requirements in Ind AS 109, Financial Instruments, prospectively for transactions occurring on or the after the date of transition to Ind AS. However, an entity may apply the derecognition requirements retrospectively from a date chosen by it if the information needed to apply Ind AS 109 to financial assets and financial liabilities derecognised as a result of past transactions was obtained at the time of initially accounting for those transactions.

d. Excise Duty

Under the previous GAAP excise duty was netted off against sale of products. However, under Ind AS, excise duty is included in sale of products and is separately presented as expense in the statement of profit and loss.

1 Property, Plant and Equipment

Under Ind AS, Property Plant and Equipment and Capital Work in Progress is reduced by the processing fees value amortised as per Effective Interest Rate (EIR) method.

2 Investment

Under the previous GAAP investments in equity instruments of subsidiaries were classified as longterm investments and were carried at cost less provision for other than temporary decline in the value of such investments. Ind AS, allow first-time adopters to use a ‘deemed cost'' of either fair value or the carrying amount under previous accounting practice to measure the initial cost of investments in subsidiaries in the separate financial statements. The Company has elected to measure investment in Lifezen Healthcare Pvt Ltd at fair value as of the transition date. The resulting fair value changes of these investments amounting to Rs. 116.00 have been recognised in retained earnings as at the date of transition. This decreased the retained earnings by Rs. 116.00 as at 1st April, 2016.

3 Proposed Dividend

Under the previous GAAP dividends proposed by the board of directors after the balance sheet date but before the approval of the financial statements were considered as adjusting events and accordingly, provision for proposed dividend was recognised as a liability. Under Ind AS, such dividends are recognised when the same is approved by the shareholders in the general meeting. As a result, liability for dividend is a non-adjusting event. Accordingly, the liability for proposed dividend as at 1st April, 2016 included under provisions in the previous GAAP has been reversed with corresponding adjustment to retained earnings. Consequently, the total equity has been increased by an equivalent amount.

4 Retained Earnings

Retained earnings as at 1st April, 2016 has been adjusted consequent to the above Ind AS transition adjustments.

5 Re-measurements of Post Employment Benefit Obligation

Under Ind AS, re-measurements i.e. actuarial gains and losses and the return on plan assets, excluding amounts included in the net interest expense on the net defined benefit liability are recognised in other comprehensive income instead of profit and loss. Under the previous GAAP these remeasurements were forming part of the Statement of Profit and Loss for the year.

6 Revenue from operations and Excise

Under previous GAAP revenue from sale of goods was presented net of excise duty on sales. Under Ind AS, revenue from sale of goods is presented inclusive of excise duty. Excise duty is presented in the Statement of Profit and Loss as a separate line item. This has resulted in an increase in the revenue from operations and expenses for the year ended 31st March, 2017. The total comprehensive income for the year ended and equity as at 31st March, 2017 has remained unchanged.

7 Deferred Tax

Deferred tax under Ind AS has been recognized for temporary differences between tax base and the book base of the relevant assets and liabilities. Under IGAAP the deferred tax was accounted based on timing differences impacting the profit or loss for the period.


Mar 31, 2016

1. Unclaimed dividends on equity shares

Year Amount in ''

2008-09 1,72,169

2012-13 1,66,082

2013-14 2,26,473

2014-15 2,35,886 Total 8,00,611

Unpaid dividend amounting to Rs,1,87,786 pertaining to FY 2007-08 was transferred to Investor Education and Protection Fund during the current reporting period.

2. Balances of sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any

3. In the opinion of the board of director''s adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

4. The company''s significant leasing arrangements are in respect of operating leases for premises (office, stores, god owns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable is charged as rent under note 26.

5. The company has reclassified previous year figures to conform to current year''s classification.


Mar 31, 2015

1. Corporate Information

Bal Pharma Limited (the company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act, 1956. Its shares are listed on two recognized stock exchanges in India. The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

2. Basis of preparation

The financial statements of the company have been prepared in accordance with Indian Generally Accepted Accounting Principles ('GAAP') under the historical cost convention on the accrual basis. The Company has prepared these financial statements to comply in all material respects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006, (as amended) which continue to apply as per Section 133 of the Companies Act, 2013 (the Act) read with rule 7 of the Companies (Accounts) rules, 2014, and other recognized accounting practices and policies generally accepted in India.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use. The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

b. Terms/Rights attached to Equity shares

The company has only one class of equity shares having par value of ' 10 per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c. Aggregate number of bonus shares issued, shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting period : Nil (31 March 2014 : Nil)

d. The company had issued total 90,400 shares (31 March 2014: 90,400 ) during the period of five years immediately preceding the reporting date on exercise of options granted under the employee stock option plan (ESOP) wherein part consideration was received in form of employee services.

As per records of the company, including its register of shareholders/members and other declaration received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

f. Shares reserved for issue under options

i. During the FY 2012-13, 2,298,748 preferential share warrants convertible into equivalent number of equity shares of Rs. 10/- each at a premium of Rs. 11 per share, had been issued to the promoters/strategic investors by the company on 19 October 2012. During the year, the preferential share warrants outstanding as at 1 April 2014 got converted in to equivalent number of equity shares.

ii. During the year 1,300,000 preferential share warrants convertible into equivalent number of equity shares of Rs. 10/- each at a premium of Rs. 52 per share, had been issued to the under mentioned strategic investors by the company on 18 August 2014, from whom 25% of the issue price amounting to Rs. 20,150,000 has been received in advance entitling the warrant holder to apply for an equivalant number of equity shares on payment of balance 75% of the issue price within 18 months from the date of allotment of warrants. As on 31 March 2015 all the warrants are outstanding and equivalent number of equity share are reserved for issue against the same. Balance amount outstanding against these warrants amounts to Rs. 60,450,000.

a. Term loan obtained from EXIM Bank of Rs. 6.00 Crores towards expansion of research & development centre at Bangalore and expenditure pertaining to R&D activities, is secured by pari passu first charge on the entire moveable fixed assets of the company by way of hypothecation and pari passu first charge by way of equitable mortgage on all immovable fixed assets of the company, both present and future, more particularly unit1, unit 2, unit 3 & Unit 4 of the company and personal guarantee of managing director. The loan is repayable in 20 equal quarterly installment of Rs. 0.30 Crore each, starting from April 2015 and carries interest @ EXIM bank LTMLR plus 250 basis points, which is currently @ 12.70%.

b. During the year the company was sanctioned a term loan of Rs. 23.45 Crores by Corporation Bank towards up gradation and expansion of the manufacturing facilities at unit 1,2 & 4. The loan is secured by Mortgage on paripassufirst charge with EXIM bank of the industrial property at unit 1, 2 & 4 and Hypothecation on pari passu first charge basis with EXIM bank of the entire movable fixed assets of the company, both present and future, belonging to unit 1, unit 2 & 4 of the company. The loan is repayable in 80 installments after a moratorium period of 24 months and carries interest @ 14%. An amount of Rs. 0.75 crores was availed as at 31 March 2015 against the said sanction.

c. The vehicle loans are secured by hypothecation of vehicles taken on loan.

3. Export benefits:

The Company has accounted an amount of Rs. 43,125,370 (31 March 2014: Rs. 35,919,992) being the net amount of credit under various export incentive schemes as announced under Foreign trade Policy. The same will be either received in cash or utilized for off-setting customs duty on future imports. The accumulated amount outstanding on this account as on 31 March 2015 is Rs. 45,585,361 (31 March 2014: Rs. 51,522,074) and the same is reflected under short-term loans and advances.

4. Based on the information available with the company, principal amount due to micro and small enterprises is 1,119 (31 March 2014: Rs. 1,635). Further interest paid during the year and interest due at the end of the year to micro and small enterprises is Rs. Nil (31 March 2014: Rs. Nil).

5. Expenditure on research and development:

An amount of Rs. 16,632,682 (31 March 2014: Rs. 13,050,019) has been incurred during the year on research and development of new products and processes in the R & D centre. Amount written off during the year on account of the above was Rs. 16,560,061 (31 March 2014: Rs. 15,025,617). The balance on this account as on 31 March 2015: Rs. 48,245,654 (31 March 2014: Rs. 48,655,922).

6. The company has provided for Rs. 2,42,414/- (31 March 2014: Rs. 262,215) being excise duty on finished goods lying at various manufacturing units at the end of reporting period.

7. Contingent liabilities not provided for:

- Letter of credit Rs. 103,179,442 (31 March 2014: Rs. 1,44,441,190)

- Estimated value of contracts remaining to be executed on capital account and not provided for Rs. 28,332,935 (31 March 2014: Rs. 2,878,000)

- Claims against company not acknowledged as debts comprises:

Amount in Rs. Nature 31 March 2015 31 March 2014

Excise & Customs 24,514,120 6,050,923

Service Tax 10,836,228 10,836,228

Sales Tax 1,788,034 1,788,034

Income Tax 8,950,439 -

Total (*) 46,088,821 18,675,185

(*) Pre - deposit under protest Rs. 643,729 (Previous year Rs. 777,006)

- The company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

8. The company has given counter guarantees to bank against guarantees issued by them on behalf of the company Rs. 31,441,990 (31 March 2014: Rs. 18,997,040).

9. Effective from 1 April 2014, the Company has changed the depreciation charge based on revised remaining useful lives of the assets as per requirement of schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the year ended 31 March 2015 is higher by Rs.17,327,086. Further, based on transitional provisions as provided in Schedule II, an amount of Rs. 7,010,983 (net of deferred tax) has been charged to accumulated retained earnings (Surplus) in respect of asset whose remaining useful life is nil as on 1 April 2014.

10. Segment information

The company is primarily engaged in a single business segment of manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and export markets represent geographical segments.

11. Balances of sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.

12. In the opinion of the board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

13. The company's significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under note 26.

14. The company has reclassified previous year figures to conform to current year's classification.


Mar 31, 2014

1. Corporate Information

Bal Pharma Limited (the company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act, 1956. Its shares are listed on two recognized stock exchanges in India. The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

2. Basis of preparation

The financial statements of the company have been prepared and presented in accordance with Indian Generally Accepted Accounting Principles (''GAAP'') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under the Companies (Accounting Standards) Rules, 2006, (as amended), other pronouncements of Institute of Chartered Accountants of India and the relevant provisions of Companies Act, 1956.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use. The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

a. Terms/Rights attached to Equity shares

The company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

b. Aggregate number of bonus shares issued, shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting period : Nil (31 March 2013 : Nil)

c. The company had issued total 90,400 shares (31 March 2013: 1,27,400 ) during the period of five years immediately preceding the reporting date on exercise of options granted under the employee stock option plan (ESOP) wherein part consideration was received in form of employee services.

As per records of the company, including its register of shareholders/members and other declaration received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

d. Shares reserved for issue under options

i. During the FY 2012-13, 2,298,748 preferential share warrants convertible into equivalent number of equity shares of Rs. 10/- each at a premium of Rs. 11 per share, had been issued to the under mentioned promoters/strategic investors by the company on 19 October 2012, from whom 25% of the issue price amounting to Rs. 12,068,441 had been received in advance entitling the warrant holder to apply for an equivalent number of equity shares on payment of balance 75% of the issue price within 18 months from the date of allotment of warrants. As on 31 March 2014 warrants issued to Anita Siroya got converted into equity share capital on receipt of the balance amount of the issue price. All other warrants are outstanding as at 31 March 2014 and equivalent number of equity shares are reserved for issue against the same. Balance amount outstanding against these warrants amounts to Rs. 19,616,734.

e. Term loan obtained from EXIM Bank of Rs. 6.00 Crores towards the expansion of research & development centre at bangalore and expenditure pertaining to R&D activities, is secured by pari pasi first charge on the entire moveable fixed assets of the company by way of hypothecation and pari pasu first charge by way of equitable mortagage on all immovable fixed assets of the company, both present and future, more particularly unitI, unit 2, unit 3 & Unit 4 of the company and personal guarantee of managing director. The loan is repayable in 20 equal quarterly installment of Rs. 0.30 Crore each, starting from April 2015 onwards and carries interest @ Exim bank LTMLR plus 250 basis points, which is currently @ 12.70%.

f. Term loan of Rs. 0.90 Crores obtained from Kotak Mahindra Prime Ltd is secured by hypothecation of vehicles and is repayable in 28 equal monthly installments of Rs. 3,78,637/- each and carries interest @ 14.73%. There are 9 monthly installments outstanding as on 3! March 2014.

g. The vehicle loans are secured by hypothication of vehicles taken on loan.

Short term borrowings from banks obtained under consortium arrangement with pari passu charge is secured by hypothecation of stock and book debts and second charge on all movable fixed assets. Cash credit is repayable on demand and carries interest rate @ 13.45% p.a to 15.50% p.a.

3. Export benefits:

The Company has accounted an amount of Rs. 35,919,992 (31 March 2013: Rs. 28,065,977) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 31 March 2014 is Rs. 51,522,074 (31 March 2013: Rs. 40,181,523) and the same is reflected under short-term loans and advances.

4. Based on the information available with the company, principal amount due to micro and small enterprises is Rs. Nil (31 March 2013: Rs. Nil). Further interest paid during the year and interest due at the end of the year to micro and small enterprises is Rs. Nil (31 March 2013: Rs. Nil).

5. Expenditure on research and development:

An amount of Rs. 13,050,019 (31 March 2013: Rs. 11,637,462) has been incurred during the year on research and development of new products and processes in the R & D Centre. Amount written off during the year on account of the above was Rs. 15, 025,617 (31 March 2013: Rs. 16, 972,153). The balance on this account as on 31 March 2014: Rs. 48,655,922 (31 March 2013: Rs. 50,631,520).

6. The Company has provided for Rs. 262,215 (31 March 2013: Rs. 496,053) being excise duty on finished goods lying at various manufacturing units at the end of reporting period.

7. Contingent liabilities not provided for:

* Letter of credit Rs. 144,441,190 (31 March 2013: Rs. 102,553,564)

* Estimated value of contracts remaining to be executed on capital account and not provided for Rs. 2,878,000 (31 March 2013: Rs. 3,585,644)

* Claims against company not acknowledged as debts comprises:

Amount in Rs.

Nature 31 March 2014 31 March 2013

Excise & Customs 6,050,923 4,094,194

Service Tax 10,836,228 10,836,228

Sales Tax 1,788,034 749,720

Total (*) 18,675,185 (*) 15,680,142

(*) Pre - deposit under protest Rs. 777,006 (Previous year Rs. 517,006)

* The Company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

8. The company has given counter guarantees to bank against guarantees issued by them on behalf of the company Rs. 18,997,040 (31 March 2013: Rs. 11,222,098).

9. Segment information

The company is primarily engaged in a single business segment of manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and export markets represent geographical segments.

10. Balances of sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.

11. In the opinion of the board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

12. The company''s significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under note 26.

13. The company has reclassified previous year figures to conform to current year''s classification.


Mar 31, 2013

1. Corporate Information

Bal Pharma Limited (the company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act, 1956. Its shares are listed on two recognized stock exchanges in India. The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

2. Basis of preparation

The financial statements of the company have been prepared and presented in accordance with Indian General Accepted Accounting Principles (''GAAP'') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under the Companies (Accounting Standards) Rules, 2006, (as amended), other pronouncements of Institute of Chartered Accountants of India and the relevant provisions of Companies Act, 1956.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use. The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

3. During the year, company reclassified authorized share capital of 4,00,000 redeemable preferential shares of Rs. 100 each in to 40,00,000 equity shares of Rs. 10 each, in order to accommodate the proposed preferential issue of share warrants and with a perception of non utilization of redeemable preferential shares in foreseeable future after necessary special resolution passed at the Annual General Meeting held on 21 September 2012. Consequently, the current authorized share capital of the company, post reclassification of redeemable preferential shares isRs. 15,00,00,000/-divided into 1,50,00,000 equity shares of Rs. 10 each.

4. Export benefits:

The Company has accounted an amount of Rs.28,065,977 (3 I March 2012: Rs.23,594,720) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 3 I March 2013 is f40,181,523 (31 March 2012: Rs.27,186,366) and the same is reflected under short-term loans and advances.

5. Based on the information available with the company, principal amount due to micro and small enterprises is f Nil (3 I March 2012: Rs.Nil). Further interest paid during the year and interest due at the end of the year to micro and small enterprises is f Nil (3 I March 2012: Rs.Nil).

6. Expenditure on research and development:

An amount of f I 1,637,462 (31 March 2012: Rs. I 1,398,007) has been incurred during the year on research and development of new products and processes in the R & D Centre. The same is proposed to be amortized over a period of 10 years commencing from the year of commercial production. Amount written off during the year on account of the above was Rs. 16,972,153 (3 I March 2012: Rs. 14,183,620). The balance on this account as on 3 I March 2013: Rs.50,63 1,520 (3 I March 2012: Rs.55,966,2I I).

7. Related party disclosures:

Name of related parties and related party relationship

Related parties where control/significant influence exist or with whom transactions have taken place during the year:

i. Enterprises where principal/ promoter shareholders have control or significant influence (Significant interest entities): Micro Labs Ltd - Enterprise owned by some of the promoter shareholders

ii. Others:

Desa Marketing International - Enterprise owned by the managing director of the company

Siroya Developers (P) Ltd. - Enterprise owned by relatives of managing director of the company

Siroya Constructions - Enterprise over which the managing director of the company exercises joint control with other partners

Siroya Wellness - Enterprise over which the managing director of the company exercises joint control with other partners

Key managerial personnel represented on the board

Shailesh D Siroya - Managing director (MD)

Dr.SPrasanna - Whole time director (WTD)

ShrenikD Siroya - Director

8. The Company has provided for Rs. 496,053 (3 I March 2012:Rs. 634,716) being Excise Duty on Finished Goods lying at various manufacturing units at the end of reporting period.

9. Contingent liabilities not provided for:

Letter of credit Rs. 102,553,564 (3 I March 2012: Rs. 137,439,654)

Estimated value of contracts remaining to be executed on capital account and not provided for Rs. 3,585,644 (3 I March 2012:Rs. 4,490,588)

Claims against company not acknowledged as debts comprises:

10. The company has given counter guarantees to bank against guarantees issued by them on behalf of the company Rs. I 1,222,098 (3 I March 2012:Rs. 13,672,151).

11. Employee stock option scheme

Bal Pharma Limited''s Employee stock option scheme - 2006 (ESOP 2006) : The Company instituted the 2006 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on 23-09-2004. The Scheme covers all non promoter directors and employees and its subsidiaries. Under the scheme, the compensation Committee of the Board (''the Committee'') shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.

The market value of a share on each grant date is defined as the average of the two weeks high and low price of the share preceding the date of grant of option on the stock exchange where there is highest trade volume during that period.

In case of termination of employment, all non-vested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the time prescribed under each option agreement by the Committee, failing which they would stand cancelled.

The company under ESOP-2006 had granted 2,19,500 options to eligible employees. The vesting period for the options granted varies from 12 to 60 months.

12. Segment information

The Company is primarily engaged in a single business segment of manufacturing and marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and Export Markets represent geographical segments.

13. Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any

14. In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

15. The Company''s significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under note 26.

16. The company has reclassified previous year figures to conform to this year''s classification.


Mar 31, 2012

1. Corporate Information

Bal Pharma Limited (the company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act, 1956. Its shares are listed on two recognized stock exchanges in India. The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

2. Basis of preparation

The financial statements of the company have been prepared and presented in accordance with Indian Generally Accepted Accounting Principles ('GAAP') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under the Companies (Accounting Standards) Rules, 2006, (as amended), other pronouncements of Institute of Chartered Accountants of India and the relevant provisions of Companies Act, 1956.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use. The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

a. Terms/Rights attached to equity shares

The company has only one class of equity shares having par value of Rs..10 per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

In addition, the company has issued total 127,400 shares (31 March 2011: 37,000 ) during the period of five years immediately preceding the reporting date on exercise of options granted under the employee stock option plan (ESOP) wherein part consideration was received in form of employee services.

As per records of the company, including its register of shareholders/members and other declaration received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

b. Shares reserved for issue under options

For details of shares reserved for issue under the employee stock option plan (ESOP) of the company, please refer note no. 40.

a. Term Loan from State Bank of India of Rs.. 2.30 Crores obtained during the financial year 2009-10 and repayable in 10 monthly installments of Rs.. 23 Lakh each. The term is secured by hypothecation of assets of Unit II and Unit III, and Unit IV funded by them. Term loan is further secured by collateral securities & personal guarantees of Directors and carries interest rate @ 16.5%.

b. Term loans obtained from EXIM Bank of Rs..21.55 Crores towards establishment of Formulation Plant at Uttaranchal and repayable in quarterly installments. The term loan is secured by first pari passu charge on the entire immovables and Hypothecation of whole of moveable fixed as- sets, both present and future of the Company including:

i. Moveable plant and machinery, Equipment, Appliances, furniture, vehicles, machinery spares and stores, tools and accessories, whether or not installed.

ii. Related movables in the course of transit or delivery whether now belonging or which may hereafter belong to the Company or which may be held by any person at any place within or outside India to the order or disposition of the company and all document or title including bills of lading, shipping documents, policies of insurance and other instruments and documents relating to such movables together with benefits of all rights thereto. Term loan is further secured by collateral securities & personal guarantees of Directors and carries interest rate @ 12%.

c. The vehicle loans are secured by hypothecation of vehicles taken on loan.

Short term borrowings from banks is secured under a Consortium arrangement with pari passu charge is secured by hypothecation of stock and book debts and second charge on all the movable fixed assets. Cash credit is repayable on demand and carries interest rate @ 14.50% p.a to 15.25% p.a.

3. export benefits:

The Company has accounted an amount of Rs.. 23,594,720 (31 March 2011: Rs. 16,875,462) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 31 March 2012 is Rs.27,186,366 (31 March 2011: Rs. 21,118,281) and the same is reflected under short-term loans and advances.

4. Based on the information available with the company, principal amount due to micro and small enterprises is Rs. Nil (31 March 2011: Rs. Nil). Further interest paid during the year and interest due at the end of the year to micro and small enterprises is Rs. Nil (31 March 2011: Rs. Nil).

5. expenditure on research and development:

An amount of Rs. 11,398,007 (31 March 2011: Rs. 12,805,725) has been incurred during the year on research and development of new products and processes in the R & D Centre. The same is proposed to be amortized over a period of 10 years commencing from the year of commercial production. Amount written off during the year on account of the above was Rs.14,183,620 (31 March 2011: Rs.5,458,572). The balance on this account as on 31 March 2012: Rs. 55,966,211 (31 March 2011: Rs. 58,751,824).

6. Related party disclosures:

- Name of related parties and related party relationship

Related parties where control/significant influence exist or with whom transactions have taken place during the year:

i. Erstwhile subsidiary - Basav Chem Limited

ii. Enterprises where principal/ promoter shareholders have control or significant influence (Significant interest entities):

Micro Labs Ltd - Enterprise owned by some of the promoter shareholders

iii. Others:

Desa Marketing International - Enterprise owned by the Managing director of the Company Siroya Developers (P) Ltd. - Enterprise owned by relatives of Managing director of the company

Siroya Constructions - Enterprise over which the Managing director of the company exercises joint control with other partners

Siroya Wellness - Enterprise over which the Managing director of the company exercises joint control with other partners

Key managerial personnel represented on the board

Shailesh D Siroya - Managing director (MD)

Dr. S P Prasanna - Whole time director (WTD)

Shrenik D Siroya - Director

7. The Company has provided for Rs. 1,231,948 (31 March 2011: Rs. 1,227,343) being Excise Duty on Finished Goods lying at various manufacturing units at the end of reporting period.

8. Contingent liabilities not provided for:

- Guarantees issued by Company's bankers Rs.13,672,151 (31 March 2011: Rs.11,452,970)

- Letter of credit Rs. 137,439,654 (31 March 2011: Rs. 111,713,626)

- Estimated value of contracts remaining to be executed on capital account and not provided for Rs. 4,490,588 (31 March 2011: Rs. NIL)

- The claim of duty and penalty of Rs 868,598 for the period May 2000 to November 200! by Central Excise in respect of Unit III is being contested and under the directions of CESTAT , Mumbai a pre-deposit of Rs. 30,000 has been made. The same is still pending decision.

- A Sales Tax claim of Rs. 749,720 on treating stock transfer as sales in Ernakulam by the Commercial Taxes, Special Circle !, KGST is being contested and a deposit of Rs. 253,729 has been made. The application is being heard by the Deputy Commissioner, Ernakulam and is still pending decision.

- The Company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

9. Employee stock option scheme

Bal Pharma Limited's Employee stock option scheme - 2006 (ESOP 2006) : The Company instituted the 2006 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on 23-09-2004. The Scheme covers all non promoter directors and employees and its subsidiaries. Under the scheme, the compensation Committee of the Board ('the Committee') shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.

The market value of a share on each grant date is defined as the average of the two weeks high and low price of the share preceding the date of grant of option on the stock exchange where there is highest trade volume during that period.

In case of termination of employment, all non-vested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the time prescribed under each option agreement by the Committee, failing which they would stand cancelled.

The company under ESOP-2006 had granted 2, 19,500 options to eligible employees. The vesting period for the options granted varies from 12 to 60 months.

10. Segment information

The Company is primarily engaged in a single business segment of manufacturing and marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and Export Markets represent geographical segments.

11. Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any

12. In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

13. The Company's significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under note 26.

14. Accounting for amalgamation

The Honorable High Court of Karnataka, on 26 August 2011, sanctioned a scheme of amalgamation (the scheme) under sections 391 to 394 of the Companies Act, 1956. In accordance with the scheme, Basav Chem Limited (transferor company) merges with the company with retrospective effect from 1 April 2009. However, since the sanction to the scheme was given during the year, the assets and liabilities of the transferor company stands transferred to and vested in the company with effect from 1 April 2011. The transferor company was engaged in the business of manufacture of pharmaceutical products. The amalgamation is expected to channelize synergies and lead to better utilization of available resources and result in greater economies of scale.

The accounting treatment has been given as per the scheme as sanctioned by the Honorable High court of judicature of Karnataka and accordingly the assets, liabilities and reserves of Basav Chem Limited., as at 1 April 2011 have been accounted under the pooling of interest method.

The company's investment in the equity share capital of Basav Chem Limited, aggregating to Rs.500,000/- stands cancelled on amalgamation and the excess of net assets of transferor company over the cost of investment amounting to Rs. 500,000 has been adjusted to reserves as per the order of Karnataka High Court.

As a result of above, figures in respect of current financial year are not comparable with those of previous financial year.

15. Disclosure as required under Accounting Standard 14 - Accounting for Amalgamation:

- Name of the Amalgamating company: Basav Chem Limited

- Nature of its business: Manufacture of pharmaceutical products

- Effective date of amalgamation for accounting purposes: 01 April 2011

- Method of accounting used to reflect amalgamation: The pooling of interest method

- Particulars of scheme sanctioned: Scheme sanctioned by the Honorable High Court of Karnataka, Bangalore through order dated 26 August 2011.

- Description and number of shares issued, together with the percentage of company's equity shares exchanged to effect the amalgamation : Not applicable

- The amount of any difference between the consideration and the value of net identifiable assets acquired and treatment thereof: Not applicable

16. Till the year ended 31 March 2011, the company was using pre-revised schedule VI to the companies Act 1956, for preparation and presentation of its financial statements. During the year ended 31 March 2012, the revised schedule VI notified under the companies Act,1956, has become applicable to the company. The company has reclassified previous year figures to conform to this year's classification.


Mar 31, 2010

1) National Savings Certificates have been deposited with Commercial Tax Department.

2) EXPORT BENEFITS:

The Company has accounted an amount of Rs 13,832,643/- (P.Y.Rs 6,563,942/-) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 31.03.2010 is Rs 11,415,647/- (P.Y. Rs 9,131,052/-) and the same is reflected under loans and advances.

3) MARKET DEVELOPMENT EXPENSES:

Expenditure incurred on Market development amounting to Rs 228,984/- (P.Y.Rs 228,984/-) has been written off during the year. Balance on this account as on 31.03.2009 is Rs 9, 15,967/- (P.Y.Rs 1,144,951/-).

4) RESEARCH & DEVELOPMENT REVENUE EXPENSES:

An amount of Rs 8,530,889/- (P.Y. Rs 8,733,504/-) has been incurred during the year on research and development of new products and processes in the R & D Centre. The same is proposed to be amortized over a period of 10 years commencing from the year of commercial production. Amount written off during the year on account of the above was Rs 5,045,057/- (P.Y. Rs 5,428,106/-). The balance on this account as on 31.03.2010 is Rs 51,404,671/- (P.Y. Rs 47,918,839/-).

5) During the year an amount of Rs NIL (P.Y. Rs 25,133,403/-) being interest on term loans for acquisition of qualifying capital assets was capitalised.

6) The Company has provided for Rs 7, 15,595 /- (P.Y. Rs. 5, 99, 217/-) being Excise Duty on Finished Goods lying at various manufacturing units as at 31.03.2010.

7) CONTINGENT LIABILITIES NOT PROVIDED FOR ( in Rupees)

a) Guarantees issued by Companys bankers Rs. 6,810,977/- (P.Y. Rs. 20,936,720/-)

b) Letter of credit Rs. 54,582,725/- (P.Y. Rs 71,135,406/- ).

c) Estimated value of contracts remaining to be executed on capital account and not provided for Rs. NIL /- (P.Y. Rs. 1,434,335/-).

8) Gratuity Plan:

The following table set out the status of the plan as required under AS 15(revised):

9) SECURITY FOR LOANS IN SCHEDULE (3) TO BALANCE SHEET:

9.1 Hire purchase finance provided by various financial institutions is secured by a charge on the assets financed by the respective institutions.

9.2 The Working Capital Loan financed by Canara Bank, ICICI Bank, Punjab National Bank, and EXIM Bank under a Consortium arrangement with pari passu charge is secured against hypothecation of stock and book debts and first charge on fixed assets other than those financed by the term lending institutions.

9.3 Loan obtained from State Bank of Indore is secured by hypothecation of assets of Unit II and Unit III, and Unit IV funded by them.

9.4 Secured loans obtained from EXIM Bank of Rs .21.55 Crores towards establishment of Formulation Plant at Uttaranchal first pari pause charge on the entire immovable and Hypothecation of whole of moveable fixed assets, both present and future of the Company including.

(a) Movable plant and machinery, Equipment, Appliances, furniture, vehicles, machinery spares and stores, tools and accessories, whether or not installed and

(b) Related movables in the course of transit or delivery whether now belonging or which may hereafter belong to the Company or which may be held by any person at any place within or outside India to the order or disposition of the company and all document or title including bills of lading, shipping documents, policies of insurance and other instruments and documents relating to such movables together with benefits of all rights thereto.

9.5 All the Secured Loans have been guaranteed by two Directors including Managing Director in their personal Capacity.

10) Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.

11) In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

12) The Companys significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under Schedule 17.

13) EMPLOYEE STOCK OPTION SCHEME

Bal Pharma Limiteds Employee Stock Option Scheme – 2006 (ESOP 2006) : The Company instituted the 2006 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on 23-09-2004. The Scheme covers all non promoter directors and employees and its subsidiaries. Under the scheme, the compensation Committee of the Board (the Committee) shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.

The market value of a share on each grant date is defined as the average of the two weeks high and low price of the share preceding the date of grant of option on the stock exchange where there is highest trade volume during that period.

In case of termination of employment, all non-vested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the time prescribed under each option agreement by the Committee, failing which they would stand cancelled.

The company under ESOP-2006 had granted 2, 19,500 options to eligible employees. The vesting period for the options granted varies from 12 to 60 months.

14) During the year, Novosynth Research labs Private Limited, a 100% subsidiary of Bal Pharma Limited applied for striking off its name from the register as defunct company under section 560 of the Companies Act, 1956. Pursuant to the above, the company has provided for diminution in the value of its investment in the said subsidiary

15) RELATED PARTY DISCLOSURES:

A. The related parties where control exists are the subsidiaries. There are no other parties over which the Company has control.

B. Related parties where control / significant influence exist or with whom transactions have taken place during the year:

i) Subsidiaries: Basav Chem Limited

Novosynth Research Labs Private Ltd

ii) Enterprises where principal / promoter shareholders have control or significant influence (Significant interest entities) : Micro Labs Ltd – Enterprise owned by some of the promoter shareholders

iii) Others:- (a) Desa Marketing International - Enterprise owned by the Managing Director of the Company.

(b) Siroya Developers (P) Ltd. - Enterprise owned by r elatives of Managing Director of the Company.

(c) Siroya Constructions - Enterprise over which the Managing Director of the Company exercis es joint control with other Partners.

C. Key managerial Personnel represented on the board:

Shailesh D.Siroya - Managing Director

Dr.S.Prasanna - Whole time Director

16) Particulars of Managerial Remuneration:

17) Computation of net profit in accordance with Section 349 of the Companies Act, 1956 :

The remuneration paid to Mr. Shailesh D Siroya, Managing Director and Dr. S. Prasanna, Wholetime Director, is in accordance with the stipulations under Schedule XIII, Part II, Section II(B) of the Companies Act, 1956, and in terms of the shareholders approval by way of special resolution in the 17th Annual General Meeting held on 23rd September 2004, and 19th Annual General Meeting held on 20th September, 2006, and 21st Annual General meeting held on 23rd September 2008 and 22nd Annual General Meeting held on 25th September 2009.

18) QUANTITATIVE INFORMATION

19) (a) The claim for differential excise duty of Rs. 1,034,757 on Physi-cian Samples demanded by the Central Excise Dept in the year 1999- 2000 was decided in Companys favor by CESTAT in the year 2006-2007. However, the Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme Court of India against the said order of CESTAT, which is still pending.

(b) The claim for differential excise duty of Rs.8.98 lakhs on physicians sales for the period September 1997 to February 1998 demanded by Central Excise Dept in respect of Unit I was contested and CESTAT, Bangalore upheld our appeal. However, Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme court of India against the said order of CESTAT, which is still pending.

(c) The claim of duty and penalty of Rs.868,598 for the period May 2000 to November 2001 by Central Excise in respect of Unit III is being contested and under the directions of CESTAT , Mumbai a pre-deposit of Rs.30,000/- has been made. The same is still pending decision.

(d) A Sales Tax claim of Rs.749,720/- on treating stock transfer as sales in Ernakulam by the Commercial Taxes, Special Circle 1, KGST is being contested and a deposit of Rs.253,729 has been made. The application is being heard by the Deputy Commissioner, Ernakulam and is still pending decision.

(e) During the year, the Income Tax Officer (TDS) raised a demand of Rs.89, 50, 429 towards non deduction of TDS under the provisions of Income Tax Act, 1961 for the assessment years 2004-05 to 2008-09 on all principal to principal purchase transactions entered into by it during the said assessment years. The company filed an appeal before the commissioner of income Tax Appeals-V- HMT Bhavan Bangalore against the said order and as per the directions of the commissioner, the company deposited 25% of the demand amounting to Rs.22, 37,610/-. The said appeal is still pending. The management is however, confident of favorable appeal order.

(f) The Company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business

20) The company, though has initiated the process, but is yet to obtain confirmation from suppliers who have registered themselves under the Micro Small Medium Enterprise Development Act, 2006 (MSMED Act, 2006). Based on the information available with the company, the balance due to Micro & Small Enterprises as defined under the MSMED Act, 2006 is Rs.NIL. Further, no interest during the year has been paid or payable under the terms of the MSMED Act, 2006.

21) Unclaimed Dividends on Equity Shares:

22) Calculation of EPS (Basic and Diluted)

23) During the financial year 2007-2008, the company entered into a share purchase agreement with the promoters and shareholders of Basav Chem Limited to acquire 100% control through purchase of existing Equity shares held by them. In accordance with the agreement, the company purchased 100,000 equity shares of Rs 10/- each @ Rs. 5/-per share and paid the amount directly to the erstwhile shareholders. Also, the Company cleared Basav Chem Ltds secured and unsecured loans. Further, during the year, the Company has already filed for amalgamation of Basav Chem limited with itself. An amount of Rs. 6,460,000/- (P.Y. 6,461,537) paid by the company towards discharge of Basav Chem Limiteds liabilities is disclosed as advance to subsidiary.

24) The Company is primarily engaged in a single business segment of manufacturing and marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and Export Markets represent geographical segments Sales by market:

25) Figures in brackets pertain to previous year.

26) Previous year figures have been regrouped /rearranged wherever necessary.

Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X